

Supplemental Table 5

Source Type	Region (Primary organization)	Test Characteristics (Test Manufacturer, Type, Sn, Sp, Regulatory Approval)	Sampling frame and method	Population Sampled	N	Dates	Adjusted	Seroprevalence (95% CI)	Confirmed Cases Per 1M	Risk of Bias (JBI)	Notes
<i>Ongoing Study</i>											
Media Report & News Release	San Miguel County, Colorado, United States (United Biomedical)	Not reported, not reported (0%, 0%, none stated)	Sampled all members of the population	General population	986	Not reported	N/A	0.8% (NR)	1,121	High	
	United States (Crush The Curve Idaho)	University of Washington has made tests available, not reported (100%, 99.6%, none stated)	Individuals volunteer to be tested and go to a testing site	Unspecified patients	1,946	Not reported	N/A	1.8% (NR)	1,046	Moderate	
	Chelsea, Massachusetts, United States (Massachusetts General Hospital)	BioMedomics, IgG, IgM LFIA (88.66%, 90.63%, none stated)	Randomly asking individuals who walked by	General Population	200	Not reported	N/A	31.5% (NR)	6,287	High	Targeting 200 people/day in main study; pilot study reported here
	New York City, New York, United States (New York State Department of Health)	New York State Department of Health Wadsworth Public Health Lab, Not reported Not reported (0%, 0%, USA FDA Emergency Use Authorization)	Random sample outside supermarkets and big-box stores	General Population	1,300	Not reported	N/A	21% (NR)	13,368	Unclear	Testing conducted over two days in April, exact dates unclear
	Long Island, New York, United States (New York State Department of Health)	New York State Department of Health Wadsworth Public Health Lab, Not reported Not reported (0%, 0%, USA FDA Emergency Use Authorization)	Random sample outside supermarkets and big-box stores	General Population		Not reported	N/A	16.7% (NR)	13,368	Unclear	Testing conducted over two days in April, exact dates unclear
	New York, United States (New York State Department of Health)	New York State Department of Health Wadsworth Public Health Lab, Not reported Not reported (0%, 0%, USA FDA Emergency Use Authorization)	Random sample outside supermarkets and big-box stores	General Population	3,000	Not reported	N/A	13.9% (NR)	13,690	Unclear	Testing conducted over two days in April, exact dates unclear
	Upstate (19 counties), New York, United States (New York State Department of Health)	New York State Department of Health Wadsworth Public Health Lab, Not reported Not reported (0%, 0%, USA FDA Emergency Use Authorization)	Random sample outside supermarkets and big-box stores	General Population		Not reported	N/A	3.9% (NR)	13,690	Unclear	Testing conducted over two days in April, exact dates unclear
	Westchester and Rockland, New York, United States (New York State Department of Health)	New York State Department of Health Wadsworth Public Health Lab, Not reported Not reported (0%, 0%, USA FDA Emergency Use Authorization)	Random sample outside supermarkets and big-box stores	General Population		Not reported	N/A	11.7% (NR)	13,368	Unclear	Testing conducted over two days in April, exact dates unclear

Supplemental Table 5

Source Type	Region (Primary organization)	Test Characteristics (Test Manufacturer, Type, Sn, Sp, Regulatory Approval)	Sampling frame and method	Population Sampled	N	Dates	Adjusted	Seroprevalence (95% CI)	Confirmed Cases Per 1M	Risk of Bias (JBI)	Notes
Media Report & News Release	Brevard County, Florida, United States (OMNI Healthcare)	Not reported, IgM, IgG LFIA (100%, 100%, USA FDA Emergency Use Authorization)	Drive through facility available to those who have previously been tested for the virus will be permitted to take an antibody test.	Individuals previously tested for COVID-19	1,000	04/17-04/24	N/A	1% (NR)	1,133	High	
	Miami, Florida, United States (Miami-Dade County & University of Miami)	BioMedomics, North Carolina, IgG, IgM Immunochromatographic test (88.66%, 90.63%, none stated)	random sampling based on age, address, other demographic information	General population		Not reported	N/A	6% (4.4-7.9%)	1,439	Unclear	Sampling started early April
	New York City, New York, United States (New York State Department of Health)	New York State Department of Health Wadsworth Public Health Lab, Not reported Not reported (0%, 0%, USA FDA Emergency Use Authorization)	Random sample outside supermarkets and big-box stores	General population		Not reported	N/A	24.7% (NR)	14,985	Unclear	Second wave of results from the New York State Study
	Long Island, New York, United States (New York State Department of Health)	New York State Department of Health Wadsworth Public Health Lab, Not reported Not reported (0%, 0%, USA FDA Emergency Use Authorization)	Random sample outside supermarkets and big-box stores	General population		Not reported	N/A	14.4% (NR)	14,985	Unclear	Second wave of results from the New York State Study
	New York, United States (New York State Department of Health)	New York State Department of Health Wadsworth Public Health Lab, Not reported Not reported (0%, 0%, USA FDA Emergency Use Authorization)	Random sample outside supermarkets and big-box stores	General Population	7,500	Not reported	N/A	14.9% (NR)	14,985	Unclear	Second wave of results from the New York State Study
	Upstate (19 counties), New York, United States (New York State Department of Health)	New York State Department of Health Wadsworth Public Health Lab, Not reported Not reported (0%, 0%, USA FDA Emergency Use Authorization)	Random sample outside supermarkets and big-box stores	General population		Not reported	N/A	3.2% (NR)	14,985	Unclear	Second wave of results from the New York State Study
	Westchester and Rockland, New York, United States (New York State Department of Health)	New York State Department of Health Wadsworth Public Health Lab, Not reported Not reported (0%, 0%, USA FDA Emergency Use Authorization)	Random sample outside supermarkets and big-box stores	General population		Not reported	N/A	15.1% (NR)	14,985	Unclear	Second wave of results from the New York State Study
	Claremont, New Hampshire, United States (ClearChoiceMD )	Quest Diagnostics, not reported (90%, 0%, none stated)	Self referral	Health care workers in the Clear Choice MD system	47	Not reported	N/A	2% (NR)	1,442	Unclear	
<b>Completed Study</b>											
Media Report & News Release	Gangelt, Heinsberg, Germany (University Hospital in Bonn)	Not reported, not reported (0%, 0%, none stated)	Not clear from main article	General Population	500	Not reported	N/A	14% (NR)	1,352	High	Actual report is in German and likely has more extraction data

Supplemental Table 5

Source Type	Region (Primary organization)	Test Characteristics (Test Manufacturer, Type, Sn, Sp, Regulatory Approval)	Sampling frame and method	Population Sampled	N	Dates	Adjusted	Seroprevalence (95% CI)	Confirmed Cases Per 1M	Risk of Bias (JBI)	Notes
	Baton Rouge, Florida, United States (Baton Rouge General Hospital)	Not reported, not reported (98.6%, 0%, none stated)	Not specified	General population	432	Not reported	N/A	4.4% (NR)	1,560	Unclear	Test was developed by the Mayo Clinic
	Los Angeles County, California, United States (University of Southern California)	Premier Biotech, IgG, IgM LFIA (80.3%, 99.5%, none stated)	Random sampling via market research firm	General Population	863	04/10-04/11	Unadjusted	4.1% (2.8-5.6%)	503	Moderate	
	Geneva, Geneva, Switzerland (University Hospitals of Geneva)	Not reported, not reported (0%, 0%, none stated)	Random sampling of individuals who previously participated in an annual health survey	General Population	343	04/06-04/10	N/A	3.5% (1.6-5.4%)	2,438	Moderate	
					417	04/14-04/17	N/A	5.5% (3.3-7.7%)	2,968	Moderate	
Singapore, Singapore (National Centre for Infectious Diseases)	Not reported, not reported (0%, 0%, none stated)	Not specified	Close contacts of infected individuals		Not reported	N/A	5.2% (NR)	2,556	Unclear	Close contacts and household members of confirmed COVID-19 patients, sometime between February-April	
Preprint	Santa Clara Valley, California, United States (Stanford University School of Medicine)	Premier Biotech, IgG, IgM LFIA (80.3%, 99.5%, none stated)	Facebook ads targeted a representative sample of the county by demographic and geographic characteristics	General Population	3,330	starting 04/03	Population Adjusted	2.8% (1.5-4.2%)	274	Moderate	
							Population & Test Adjusted	2.8% (2-3.5%)	274	Moderate	Average of range used.
							Unadjusted	1.5% (1.1-2%)	274	Moderate	
	Scotland (University of Oxford)	Not specified, IgM, IgG ELISA, Microneutralization assay (0%, 0%, none stated)	Not specified	Recent blood donors	1,000	03/17-03/23	Unadjusted	1.2% (NR)	23	High	Used UK for confirmed cases per 1M
	Paris, Oise, France (Institut Pasteur; Bichat-Claude Bernard University Hospital)	Designed by authors, IgG, IgA, IgM ELISA, S-FLOW, LIPS (0%, 0%, none stated)	Blood donor samples were taken from anonymized samples.	Recent blood donors	200	03/20-03/24	Unadjusted	3% (NR)	168	High	Positivity rate was between 1-3% with different assays
	Denmark (Aarhus University)	Livzon Diagnostics Inc, IgG, IgM LFIA (83%, 100%, none stated)	Samples from the first 9,496 individuals to donate blood in the study period were tested	Recent blood donors	9,496	04/06-04/17	Test unadjusted	1.7% (0.9-2.3%)	754	Moderate	Was adjusted for assay sensitivity and specificity
Unadjusted							1.8% (1.6-2.1%)	754	Moderate		

Supplemental Table 5

Source Type	Region (Primary organization)	Test Characteristics (Test Manufacturer, Type, Sn, Sp, Regulatory Approval)	Sampling frame and method	Population Sampled	N	Dates	Adjusted	Seroprevalence (95% CI)	Confirmed Cases Per 1M	Risk of Bias (JBI)	Notes
	Oise, France (Institut Pasteur; Sorbonne Université)	Institut Pasteur, IgG ELISA, S-FLOW, LIPS (0%, 99%, none stated)	Pupils, family members and staff were invited via email to participate in the investigation	High school staff (non-teachers)	27	starting 03/30	Unadjusted	59.3% (NR)	615	High	
				High school students	240	starting 03/30	Unadjusted	38.3% (NR)	615	High	
				High school teachers	53	starting 03/30	Unadjusted	43.4% (NR)	615	High	
				High school related people	661	starting 03/30	Unadjusted	25.9% (22.6-24.9%)	615	High	
				Parents of high school students	211	starting 03/30	Unadjusted	11.4% (NR)	615	High	
				Siblings of high school students	127	starting 03/30	Unadjusted	10.2% (NR)	615	High	
	Guilan, Iran (Guilan University of medical sciences)	VivaChek, IgM, IgG RDT (63.3%, 100%, none stated)	Random sampling design through phone call invitation. Institutional living centres were excluded.	General Population	551	until 04/23	Population Adjusted	21% (14-29%)	1,024	High	IFR is reported as the mean of the reported range 0.08-0.12%
							Test adjusted	33% (28-39%)	1,024	High	IFR is reported as the mean of the reported range 0.08-0.12%
							Unadjusted	22% (19-26%)	1,024	High	IFR is reported as the mean of the reported range 0.08-0.12%
	Kobe, Hyogo Prefecture, Japan (Kobe City Medical Center General Hospital)	KURABO Industries Lt, IgG Immunochromatographic test (0%, 0%, none stated)	Randomly selected preserved serum from patients who received blood testing. Fever consultation services excluded.	Outpatients from tertiary care centre (non-COVID)	1,000	03/31-04/07	Population Adjusted	2.7% (1.8-3.9%)	15	High	
							Population Adjusted	3.3% (2.3-4.6%)	15	High	
Padova, Veneto, Italy (University Hospital of Padova)	Snibe Diagnostic, IgG, IgM Chemiluminescence Immunoassay (91.21%, 97.33%, none stated)	Not specified	Health care workers	133	Not reported	Unadjusted	4.5% (NR)	3,398	High		
Government / NGO / Health System Report	Seattle, Washington, United States (University of Washington)	Not reported, not reported (0%, 0%, none stated)	Convenience sample using remnant clinical sera	Remnant clinical sera	221	Not reported	N/A	0.4% (NR)	1,964	Unclear	